Healio October 2, 2024 Read the full article >> The future of Alzheimer’s disease detection and treatment may lie in AI-based datasets encompassing an abundance of real-world evidence from a large number of patients, an expert said. Healio spoke to Carl D. Marci, MD, chief clinical officer at Boston-based OM1, to gain his insights into how his[…]
Applied Clinical Trails October 1, 2024 Watch the full video >> In this video interview with ACT editor Andy Studna, Rich Gliklich, founder of OM1 highlights personalized medicine and predicting disease outcomes. ACT: Looking forward, how will real-world evidence (RWE) drive point-of-care decisions? Gliklich: I love this question because one of the reasons we started OM1[…]
Applied Clinical Trials September 30, 2024 Watch the full video >> In this video interview with ACT editor Andy Studna, Rich Gliklich, founder of OM1 discusses automating data collection and organizing unstructured data. ACT: Is there any potential for the use of artificial intelligence (AI) in the data collection space? Gliklich: I love that question because[…]
Applied Clinical Trials September 27, 2024 Watch the full video >> In this video interview with ACT editor Andy Studna, Rich Gliklich, founder of OM1 highlights existing guidances on real-world data and where there is room for even more oversight. ACT: What are some key regulatory requirements or challenges that need to be addressed when[…]
Applied Clinical Trials September 26, 2024 Watch the full video >> In this video interview with ACT editor Andy Studna, Rich Gliklich, founder of OM1 touches on the idea of maximizing data collection. ACT: How can the integration of real-world data (RWD) reduce burden for key stakeholders in a trial such as sites, sponsors, and[…]
